Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis
Xanthine oxidoreductase (XOR) is generally known as the final enzyme in purine metabolism and as a source of reactive oxygen species (ROS). In addition, this enzyme has been suggested to mediate nitric oxide (NO) formation via reduction of inorganic nitrate and nitrite. This NO synthase (NOS)-indepe...
Gespeichert in:
Veröffentlicht in: | Free radical biology & medicine 2016-10, Vol.99, p.472-484 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 484 |
---|---|
container_issue | |
container_start_page | 472 |
container_title | Free radical biology & medicine |
container_volume | 99 |
creator | Peleli, Maria Zollbrecht, Christa Montenegro, Marcelo F Hezel, Michael Zhong, Jianghong Persson, Erik G Holmdahl, Rikard Weitzberg, Eddie Lundberg, Jon O Carlström, Mattias |
description | Xanthine oxidoreductase (XOR) is generally known as the final enzyme in purine metabolism and as a source of reactive oxygen species (ROS). In addition, this enzyme has been suggested to mediate nitric oxide (NO) formation via reduction of inorganic nitrate and nitrite. This NO synthase (NOS)-independent pathway for NO generation is of particular importance during certain conditions when NO bioavailability is diminished due to reduced activity of endothelial NOS (eNOS) or increased oxidative stress, including aging and cardiovascular disease. The exact interplay between NOS- and XOR-derived NO generation is not fully elucidated yet. The aim of the present study was to investigate if eNOS deficiency is associated with changes in XOR expression and activity and the possible impact on nitrite, NO and ROS homeostasis. Plasma levels of nitrate and nitrite were similar between eNOS deficient (eNOS
) and wildtype (wt) mice. XOR activity was upregulated in eNOS
compared with wt, but not in nNOS
, iNOS
or wt mice treated with the non-selective NOS inhibitor L-NAME. Following an acute dose of nitrate, plasma nitrite increased more in eNOS
compared with wt, and this augmented response was abolished by the selective XOR inhibitor febuxostat. Livers from eNOS
displayed higher nitrite reducing capacity compared with wt, and this effect was attenuated by febuxostat. Dietary supplementation with nitrate increased XOR expression and activity, but concomitantly reduced superoxide generation. The latter effect was also seen in vitro after nitrite administration. Treatment with febuxostat elevated blood pressure in eNOS
, but not in wt mice. A high dose of dietary nitrate reduced blood pressure in naïve eNOS
mice, and again this effect was abolished by febuxostat. In conclusion, eNOS deficiency is associated with an upregulation of XOR facilitating the nitrate-nitrite-NO pathway and decreasing the generation of ROS. This interplay between XOR and eNOS is proposed to play a significant role in NO homeostasis and blood pressure regulation. |
doi_str_mv | 10.1016/j.freeradbiomed.2016.09.004 |
format | Article |
fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_502536</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1835371262</sourcerecordid><originalsourceid>FETCH-LOGICAL-p286t-8e03e11b7eebd6f43c3a6abc16da51a2270d0cdbcf2cadc58caa16d4494169b33</originalsourceid><addsrcrecordid>eNp1kc1r3DAQxUVoyMe2_0IQ9NJD7erDlu3eQrpJCmEN2bb0JsbSOKvsru1YcsL-91HItuSS03u8-fEYZgj5zFnKGVff7tN2RBzBNq7fok1FDFNWpYxlB-SEl4VMsrxSH974Y3Lq_T2LRC7LI3IsCsUqIfITsp53K-gMWvq3vqVggnt0YUddR3FRLxOLrTMOu0C3zuB3Om9bNMHTvqNhhbRzYYSAyYu6qIuaDhBWT7Cj0Fl6Wy_pKu7Y-wDe-Y_ksIWNx097nZHfl_NfF9fJTX318-L8JhlEqUJSIpPIeVMgNla1mTQSFDSGKws5ByEKZpmxjWmFAWvy0gDEWZZVGVdVI-WMJK-9_gmHqdHD6LYw7nQPTu-jdXSocyZyqSL_9V3-h_tzrvvxTk-TlpwVRRnxL6_4MPYPE_qgt84b3Gygw37ympcylwUXSkT0bI9OTXzV_-Z_95fPC0GN3Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835371262</pqid></control><display><type>article</type><title>Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Peleli, Maria ; Zollbrecht, Christa ; Montenegro, Marcelo F ; Hezel, Michael ; Zhong, Jianghong ; Persson, Erik G ; Holmdahl, Rikard ; Weitzberg, Eddie ; Lundberg, Jon O ; Carlström, Mattias</creator><creatorcontrib>Peleli, Maria ; Zollbrecht, Christa ; Montenegro, Marcelo F ; Hezel, Michael ; Zhong, Jianghong ; Persson, Erik G ; Holmdahl, Rikard ; Weitzberg, Eddie ; Lundberg, Jon O ; Carlström, Mattias</creatorcontrib><description>Xanthine oxidoreductase (XOR) is generally known as the final enzyme in purine metabolism and as a source of reactive oxygen species (ROS). In addition, this enzyme has been suggested to mediate nitric oxide (NO) formation via reduction of inorganic nitrate and nitrite. This NO synthase (NOS)-independent pathway for NO generation is of particular importance during certain conditions when NO bioavailability is diminished due to reduced activity of endothelial NOS (eNOS) or increased oxidative stress, including aging and cardiovascular disease. The exact interplay between NOS- and XOR-derived NO generation is not fully elucidated yet. The aim of the present study was to investigate if eNOS deficiency is associated with changes in XOR expression and activity and the possible impact on nitrite, NO and ROS homeostasis. Plasma levels of nitrate and nitrite were similar between eNOS deficient (eNOS
) and wildtype (wt) mice. XOR activity was upregulated in eNOS
compared with wt, but not in nNOS
, iNOS
or wt mice treated with the non-selective NOS inhibitor L-NAME. Following an acute dose of nitrate, plasma nitrite increased more in eNOS
compared with wt, and this augmented response was abolished by the selective XOR inhibitor febuxostat. Livers from eNOS
displayed higher nitrite reducing capacity compared with wt, and this effect was attenuated by febuxostat. Dietary supplementation with nitrate increased XOR expression and activity, but concomitantly reduced superoxide generation. The latter effect was also seen in vitro after nitrite administration. Treatment with febuxostat elevated blood pressure in eNOS
, but not in wt mice. A high dose of dietary nitrate reduced blood pressure in naïve eNOS
mice, and again this effect was abolished by febuxostat. In conclusion, eNOS deficiency is associated with an upregulation of XOR facilitating the nitrate-nitrite-NO pathway and decreasing the generation of ROS. This interplay between XOR and eNOS is proposed to play a significant role in NO homeostasis and blood pressure regulation.</description><identifier>ISSN: 1873-4596</identifier><identifier>ISSN: 0891-5849</identifier><identifier>EISSN: 1873-4596</identifier><identifier>DOI: 10.1016/j.freeradbiomed.2016.09.004</identifier><identifier>PMID: 27609225</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Blood Pressure - drug effects ; Endothelial nitric oxide synthase ; Enzyme Inhibitors - pharmacology ; Febuxostat ; Febuxostat - pharmacology ; Gene Expression Regulation ; Hypertension ; Male ; Mice ; Mice, Knockout ; NG-Nitroarginine Methyl Ester - pharmacology ; Nitrate ; Nitrates - blood ; Nitrates - pharmacology ; Nitric oxide ; Nitric Oxide - blood ; Nitric Oxide Synthase Type I - antagonists & inhibitors ; Nitric Oxide Synthase Type I - deficiency ; Nitric Oxide Synthase Type I - genetics ; Nitric Oxide Synthase Type II - antagonists & inhibitors ; Nitric Oxide Synthase Type II - deficiency ; Nitric Oxide Synthase Type II - genetics ; Nitric Oxide Synthase Type III - antagonists & inhibitors ; Nitric Oxide Synthase Type III - deficiency ; Nitric Oxide Synthase Type III - genetics ; Nitrite ; Nitrites - blood ; Nitrites - pharmacology ; Oxidation-Reduction ; Oxidative stress ; Reactive oxygen species ; Signal Transduction ; Superoxide ; Superoxides - metabolism ; Uric acid ; Xanthine Dehydrogenase - antagonists & inhibitors ; Xanthine Dehydrogenase - genetics ; Xanthine Dehydrogenase - metabolism ; Xanthine oxidase ; Xanthine oxidoreductase</subject><ispartof>Free radical biology & medicine, 2016-10, Vol.99, p.472-484</ispartof><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27609225$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-310778$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:134585056$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Peleli, Maria</creatorcontrib><creatorcontrib>Zollbrecht, Christa</creatorcontrib><creatorcontrib>Montenegro, Marcelo F</creatorcontrib><creatorcontrib>Hezel, Michael</creatorcontrib><creatorcontrib>Zhong, Jianghong</creatorcontrib><creatorcontrib>Persson, Erik G</creatorcontrib><creatorcontrib>Holmdahl, Rikard</creatorcontrib><creatorcontrib>Weitzberg, Eddie</creatorcontrib><creatorcontrib>Lundberg, Jon O</creatorcontrib><creatorcontrib>Carlström, Mattias</creatorcontrib><title>Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis</title><title>Free radical biology & medicine</title><addtitle>Free Radic Biol Med</addtitle><description>Xanthine oxidoreductase (XOR) is generally known as the final enzyme in purine metabolism and as a source of reactive oxygen species (ROS). In addition, this enzyme has been suggested to mediate nitric oxide (NO) formation via reduction of inorganic nitrate and nitrite. This NO synthase (NOS)-independent pathway for NO generation is of particular importance during certain conditions when NO bioavailability is diminished due to reduced activity of endothelial NOS (eNOS) or increased oxidative stress, including aging and cardiovascular disease. The exact interplay between NOS- and XOR-derived NO generation is not fully elucidated yet. The aim of the present study was to investigate if eNOS deficiency is associated with changes in XOR expression and activity and the possible impact on nitrite, NO and ROS homeostasis. Plasma levels of nitrate and nitrite were similar between eNOS deficient (eNOS
) and wildtype (wt) mice. XOR activity was upregulated in eNOS
compared with wt, but not in nNOS
, iNOS
or wt mice treated with the non-selective NOS inhibitor L-NAME. Following an acute dose of nitrate, plasma nitrite increased more in eNOS
compared with wt, and this augmented response was abolished by the selective XOR inhibitor febuxostat. Livers from eNOS
displayed higher nitrite reducing capacity compared with wt, and this effect was attenuated by febuxostat. Dietary supplementation with nitrate increased XOR expression and activity, but concomitantly reduced superoxide generation. The latter effect was also seen in vitro after nitrite administration. Treatment with febuxostat elevated blood pressure in eNOS
, but not in wt mice. A high dose of dietary nitrate reduced blood pressure in naïve eNOS
mice, and again this effect was abolished by febuxostat. In conclusion, eNOS deficiency is associated with an upregulation of XOR facilitating the nitrate-nitrite-NO pathway and decreasing the generation of ROS. This interplay between XOR and eNOS is proposed to play a significant role in NO homeostasis and blood pressure regulation.</description><subject>Animals</subject><subject>Blood Pressure - drug effects</subject><subject>Endothelial nitric oxide synthase</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Febuxostat</subject><subject>Febuxostat - pharmacology</subject><subject>Gene Expression Regulation</subject><subject>Hypertension</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>NG-Nitroarginine Methyl Ester - pharmacology</subject><subject>Nitrate</subject><subject>Nitrates - blood</subject><subject>Nitrates - pharmacology</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - blood</subject><subject>Nitric Oxide Synthase Type I - antagonists & inhibitors</subject><subject>Nitric Oxide Synthase Type I - deficiency</subject><subject>Nitric Oxide Synthase Type I - genetics</subject><subject>Nitric Oxide Synthase Type II - antagonists & inhibitors</subject><subject>Nitric Oxide Synthase Type II - deficiency</subject><subject>Nitric Oxide Synthase Type II - genetics</subject><subject>Nitric Oxide Synthase Type III - antagonists & inhibitors</subject><subject>Nitric Oxide Synthase Type III - deficiency</subject><subject>Nitric Oxide Synthase Type III - genetics</subject><subject>Nitrite</subject><subject>Nitrites - blood</subject><subject>Nitrites - pharmacology</subject><subject>Oxidation-Reduction</subject><subject>Oxidative stress</subject><subject>Reactive oxygen species</subject><subject>Signal Transduction</subject><subject>Superoxide</subject><subject>Superoxides - metabolism</subject><subject>Uric acid</subject><subject>Xanthine Dehydrogenase - antagonists & inhibitors</subject><subject>Xanthine Dehydrogenase - genetics</subject><subject>Xanthine Dehydrogenase - metabolism</subject><subject>Xanthine oxidase</subject><subject>Xanthine oxidoreductase</subject><issn>1873-4596</issn><issn>0891-5849</issn><issn>1873-4596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1r3DAQxUVoyMe2_0IQ9NJD7erDlu3eQrpJCmEN2bb0JsbSOKvsru1YcsL-91HItuSS03u8-fEYZgj5zFnKGVff7tN2RBzBNq7fok1FDFNWpYxlB-SEl4VMsrxSH974Y3Lq_T2LRC7LI3IsCsUqIfITsp53K-gMWvq3vqVggnt0YUddR3FRLxOLrTMOu0C3zuB3Om9bNMHTvqNhhbRzYYSAyYu6qIuaDhBWT7Cj0Fl6Wy_pKu7Y-wDe-Y_ksIWNx097nZHfl_NfF9fJTX318-L8JhlEqUJSIpPIeVMgNla1mTQSFDSGKws5ByEKZpmxjWmFAWvy0gDEWZZVGVdVI-WMJK-9_gmHqdHD6LYw7nQPTu-jdXSocyZyqSL_9V3-h_tzrvvxTk-TlpwVRRnxL6_4MPYPE_qgt84b3Gygw37ympcylwUXSkT0bI9OTXzV_-Z_95fPC0GN3Q</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Peleli, Maria</creator><creator>Zollbrecht, Christa</creator><creator>Montenegro, Marcelo F</creator><creator>Hezel, Michael</creator><creator>Zhong, Jianghong</creator><creator>Persson, Erik G</creator><creator>Holmdahl, Rikard</creator><creator>Weitzberg, Eddie</creator><creator>Lundberg, Jon O</creator><creator>Carlström, Mattias</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DF2</scope></search><sort><creationdate>20161001</creationdate><title>Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis</title><author>Peleli, Maria ; Zollbrecht, Christa ; Montenegro, Marcelo F ; Hezel, Michael ; Zhong, Jianghong ; Persson, Erik G ; Holmdahl, Rikard ; Weitzberg, Eddie ; Lundberg, Jon O ; Carlström, Mattias</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p286t-8e03e11b7eebd6f43c3a6abc16da51a2270d0cdbcf2cadc58caa16d4494169b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Blood Pressure - drug effects</topic><topic>Endothelial nitric oxide synthase</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Febuxostat</topic><topic>Febuxostat - pharmacology</topic><topic>Gene Expression Regulation</topic><topic>Hypertension</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>NG-Nitroarginine Methyl Ester - pharmacology</topic><topic>Nitrate</topic><topic>Nitrates - blood</topic><topic>Nitrates - pharmacology</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - blood</topic><topic>Nitric Oxide Synthase Type I - antagonists & inhibitors</topic><topic>Nitric Oxide Synthase Type I - deficiency</topic><topic>Nitric Oxide Synthase Type I - genetics</topic><topic>Nitric Oxide Synthase Type II - antagonists & inhibitors</topic><topic>Nitric Oxide Synthase Type II - deficiency</topic><topic>Nitric Oxide Synthase Type II - genetics</topic><topic>Nitric Oxide Synthase Type III - antagonists & inhibitors</topic><topic>Nitric Oxide Synthase Type III - deficiency</topic><topic>Nitric Oxide Synthase Type III - genetics</topic><topic>Nitrite</topic><topic>Nitrites - blood</topic><topic>Nitrites - pharmacology</topic><topic>Oxidation-Reduction</topic><topic>Oxidative stress</topic><topic>Reactive oxygen species</topic><topic>Signal Transduction</topic><topic>Superoxide</topic><topic>Superoxides - metabolism</topic><topic>Uric acid</topic><topic>Xanthine Dehydrogenase - antagonists & inhibitors</topic><topic>Xanthine Dehydrogenase - genetics</topic><topic>Xanthine Dehydrogenase - metabolism</topic><topic>Xanthine oxidase</topic><topic>Xanthine oxidoreductase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peleli, Maria</creatorcontrib><creatorcontrib>Zollbrecht, Christa</creatorcontrib><creatorcontrib>Montenegro, Marcelo F</creatorcontrib><creatorcontrib>Hezel, Michael</creatorcontrib><creatorcontrib>Zhong, Jianghong</creatorcontrib><creatorcontrib>Persson, Erik G</creatorcontrib><creatorcontrib>Holmdahl, Rikard</creatorcontrib><creatorcontrib>Weitzberg, Eddie</creatorcontrib><creatorcontrib>Lundberg, Jon O</creatorcontrib><creatorcontrib>Carlström, Mattias</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Uppsala universitet</collection><jtitle>Free radical biology & medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peleli, Maria</au><au>Zollbrecht, Christa</au><au>Montenegro, Marcelo F</au><au>Hezel, Michael</au><au>Zhong, Jianghong</au><au>Persson, Erik G</au><au>Holmdahl, Rikard</au><au>Weitzberg, Eddie</au><au>Lundberg, Jon O</au><au>Carlström, Mattias</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis</atitle><jtitle>Free radical biology & medicine</jtitle><addtitle>Free Radic Biol Med</addtitle><date>2016-10-01</date><risdate>2016</risdate><volume>99</volume><spage>472</spage><epage>484</epage><pages>472-484</pages><issn>1873-4596</issn><issn>0891-5849</issn><eissn>1873-4596</eissn><abstract>Xanthine oxidoreductase (XOR) is generally known as the final enzyme in purine metabolism and as a source of reactive oxygen species (ROS). In addition, this enzyme has been suggested to mediate nitric oxide (NO) formation via reduction of inorganic nitrate and nitrite. This NO synthase (NOS)-independent pathway for NO generation is of particular importance during certain conditions when NO bioavailability is diminished due to reduced activity of endothelial NOS (eNOS) or increased oxidative stress, including aging and cardiovascular disease. The exact interplay between NOS- and XOR-derived NO generation is not fully elucidated yet. The aim of the present study was to investigate if eNOS deficiency is associated with changes in XOR expression and activity and the possible impact on nitrite, NO and ROS homeostasis. Plasma levels of nitrate and nitrite were similar between eNOS deficient (eNOS
) and wildtype (wt) mice. XOR activity was upregulated in eNOS
compared with wt, but not in nNOS
, iNOS
or wt mice treated with the non-selective NOS inhibitor L-NAME. Following an acute dose of nitrate, plasma nitrite increased more in eNOS
compared with wt, and this augmented response was abolished by the selective XOR inhibitor febuxostat. Livers from eNOS
displayed higher nitrite reducing capacity compared with wt, and this effect was attenuated by febuxostat. Dietary supplementation with nitrate increased XOR expression and activity, but concomitantly reduced superoxide generation. The latter effect was also seen in vitro after nitrite administration. Treatment with febuxostat elevated blood pressure in eNOS
, but not in wt mice. A high dose of dietary nitrate reduced blood pressure in naïve eNOS
mice, and again this effect was abolished by febuxostat. In conclusion, eNOS deficiency is associated with an upregulation of XOR facilitating the nitrate-nitrite-NO pathway and decreasing the generation of ROS. This interplay between XOR and eNOS is proposed to play a significant role in NO homeostasis and blood pressure regulation.</abstract><cop>United States</cop><pmid>27609225</pmid><doi>10.1016/j.freeradbiomed.2016.09.004</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1873-4596 |
ispartof | Free radical biology & medicine, 2016-10, Vol.99, p.472-484 |
issn | 1873-4596 0891-5849 1873-4596 |
language | eng |
recordid | cdi_swepub_primary_oai_swepub_ki_se_502536 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Animals Blood Pressure - drug effects Endothelial nitric oxide synthase Enzyme Inhibitors - pharmacology Febuxostat Febuxostat - pharmacology Gene Expression Regulation Hypertension Male Mice Mice, Knockout NG-Nitroarginine Methyl Ester - pharmacology Nitrate Nitrates - blood Nitrates - pharmacology Nitric oxide Nitric Oxide - blood Nitric Oxide Synthase Type I - antagonists & inhibitors Nitric Oxide Synthase Type I - deficiency Nitric Oxide Synthase Type I - genetics Nitric Oxide Synthase Type II - antagonists & inhibitors Nitric Oxide Synthase Type II - deficiency Nitric Oxide Synthase Type II - genetics Nitric Oxide Synthase Type III - antagonists & inhibitors Nitric Oxide Synthase Type III - deficiency Nitric Oxide Synthase Type III - genetics Nitrite Nitrites - blood Nitrites - pharmacology Oxidation-Reduction Oxidative stress Reactive oxygen species Signal Transduction Superoxide Superoxides - metabolism Uric acid Xanthine Dehydrogenase - antagonists & inhibitors Xanthine Dehydrogenase - genetics Xanthine Dehydrogenase - metabolism Xanthine oxidase Xanthine oxidoreductase |
title | Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T17%3A47%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhanced%20XOR%20activity%20in%20eNOS-deficient%20mice:%20Effects%20on%20the%20nitrate-nitrite-NO%20pathway%20and%20ROS%20homeostasis&rft.jtitle=Free%20radical%20biology%20&%20medicine&rft.au=Peleli,%20Maria&rft.date=2016-10-01&rft.volume=99&rft.spage=472&rft.epage=484&rft.pages=472-484&rft.issn=1873-4596&rft.eissn=1873-4596&rft_id=info:doi/10.1016/j.freeradbiomed.2016.09.004&rft_dat=%3Cproquest_swepu%3E1835371262%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835371262&rft_id=info:pmid/27609225&rfr_iscdi=true |